The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 results of the WEE1 inhibitor, azenosertib, in combination with gemcitabine (gem) in adult and pediatric patients (pts) with relapsed or refractory (R/R) osteosarcoma.
 
Viswatej Avutu
No Relationships to Disclose
 
J. Andrew Livingston
Consulting or Advisory Role - SpringWorks Therapeutics
Research Funding - Exelixis (Inst); Genentech/Roche (Inst); Repare Therapeutics (Inst)
Other Relationship - Guidepoint Global
 
Noah Federman
Stock and Other Ownership Interests - Moderna Therapeutics
Consulting or Advisory Role - Bayer; SpringWorks Therapeutics
Speakers' Bureau - Bayer; Fennec Pharma; Springworks Therapeutics
Research Funding - Mirati Therapeutics
 
Lee D. Cranmer
Research Funding - AADi; AADi (Inst); Advenchen Laboratories (Inst); Avacta Life Sciences (Inst); Boehringer Ingelheim (Inst); Exelixis (Inst); InhibRx (Inst); Iterion Therapeutics (Inst); Lilly (Inst); Merck (Inst); Monopar Therapeutics (Inst); Philogen (Inst); Salarius Pharmaceuticals (Inst); Salarius Pharmaceuticals (Inst); TRACON Pharma (Inst)
Travel, Accommodations, Expenses - AADi
 
Nathalie Gaspar
Consulting or Advisory Role - EISAI; IPSEN
Travel, Accommodations, Expenses - Eisai; EISAI
 
Maud Toulmonde
Speakers' Bureau - Blueprint Medicines
Travel, Accommodations, Expenses - PharmaMar
 
Joseph Gerald Pressey
No Relationships to Disclose
 
Mehdi Brahmi
Honoraria - Amgen; PharmaMar
Expert Testimony - Bayer; Bayer; Deciphera
Travel, Accommodations, Expenses - mundipharma; PharmaMar
 
Andrew Stewart Poklepovic
Consulting or Advisory Role - Novartis
Speakers' Bureau - Natera
 
Qing Shi
Employment - Zentalis
Stock and Other Ownership Interests - Zentalis
 
Nathan Jameson
Employment - Zentalis
Stock and Other Ownership Interests - Zentalis
Patents, Royalties, Other Intellectual Property - Zentalis
Travel, Accommodations, Expenses - Zentalis
 
Adrian Michael Jubb
Employment - BioTheryX; Flare Therapeutics; Zentalis
Leadership - Flare Therapeutics; Zentalis
Stock and Other Ownership Interests - BioTheryX; Flare Therapeutics; Zentalis
Consulting or Advisory Role - BioTheryX; Zentalis
 
Chrystal Ursula Louis
Employment - Crispr Therapeutics; Zentalis
Stock and Other Ownership Interests - CRISPR Therapeutics; Zentalis
 
Sant P. Chawla
Stock and Other Ownership Interests - AADi; Cellestia Biotech; Counterpoint; Immix BioPharma
Honoraria - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma; Tyme
Consulting or Advisory Role - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Speakers' Bureau - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
 
William D. Tap
Leadership - AstraZeneca; Atropos; Certis Oncology Solutions; Innovo Therapeutics
Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions
Consulting or Advisory Role - Adcendo; Amgen; AmMax Bio; Ayala Pharmaceuticals; Bayer; BioAtla; Boehringer Ingelheim; Cogent Biosciences; Daiichi Sankyo; Deciphera; Epizyme; Foghorn Therapeutics; inhibrx; Kowa Pharmaceutical; Lilly; Medpacto; PharmaEssential; Servier
Research Funding - Avacta Life Sciences (Inst); BioAtla (Inst); Blueprint Medicines (Inst); C4 Therapeutics (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Theseus Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329; Enigma and CDH18 as companion Diagnostics for CDK4 inhibition – SKI2016-021-03